Antibodies and utilization thereof
AssigneeTakeda Chemical Industries, Ltd.
InventorsHirokazu Matsumoto, Chieko Kitada, Shuji Hinuma
Life of this patent
Estimating the term…
Loading patent…
AssigneeTakeda Chemical Industries, Ltd.
InventorsHirokazu Matsumoto, Chieko Kitada, Shuji Hinuma
Estimating the term…
The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand. The immunoassay method using the monoclonal antibodies of the invention by the sandwich technique (in particular the sandwich technique using the monoclonal antibody and an antibody recognizing an intermediate portion of the 19P2 ligand) can assay the 19P2 ligand or a derivative thereof specifically and with high sensitivity. This assay method can be used in elucidating the physiological functions of the 19P2 ligand or a derivative thereof.
A monoclonal antibody that specifically binds to a peptide having an amino acid sequence of residues 12 to 24 of SEQ ID NO:
An isolated hybridoma cell line, having accession number NIBH 6300, said cell line producing the antibody P2L-1Ta.
Dependencies are inferred from the claim text.